herb × Hormone Health
Saw Palmetto for Prostate Health
Berry extract that inhibits 5-alpha-reductase, the enzyme converting testosterone to DHT; used for benign prostatic hyperplasia symptoms and androgenic hair thinning, though large trials show mixed results versus placebo.
4published research: study records
17published research: findings
Not formally gradedcertainty of the research
Published research
What studies found
Saw Palmetto for Prostate Health
1 of 14 results reported a benefit, from 4 published studies.
4 studies, including a review of trials · the chart counts everything measured
- 1 reported a benefit
- 13 no clear benefit
Colour keyReported a benefitNo clear benefitUnclearPossible harmAmber is for highlights, such as where the most research is. It never means a result was good.
- Prostate sizeNo clear difference1.22 cc lower1 review of trials2012 study ↗
- Urinary symptomsNo clear difference0.25 points higher1 review of trials0 of 4 results reported a benefit2012 study ↗
- Peak urine flowNo clear difference0.4 mL/s higher1 review of trials0 of 2 results reported a benefit2012 study ↗
- Treatment response rateNo clear difference4% lower risk1 review of trials2012 study ↗
- Urine left in bladderNo clear difference4.23 lower, unit not reported1 review of trials, compared with another treatment2020 study ↗
- Night-time urinationNo clear benefit foundsee exact figuresSaw palmetto did not significantly decrease nightly urination compared to placebo.1 review of trials2012 study ↗
Also measured in these studies (2)
These were measured alongside, but they are not what this condition is about.
- Prostate-related quality of lifeReported a benefitsee exact figuresProstate-specific concerns improved in the saw palmetto group compared to placebo in 21 men over 22 weeks.1 randomised trial2016 study ↗
- Quality of lifeNo clear difference1.51 higher, unit not reported1 review of trials, compared with another treatment0 of 2 results reported a benefit2020 study ↗
1 laboratory marker also measured
- Prostate blood marker (PSA) · lab markerNo clear difference0.46 higher, unit not reported1 review of trials, compared with another treatment2020 study ↗
Side effects: measured in 3 results. No result reported more side effects than the comparison group.
These are the figures the studies reported, not a prediction for any one person. Where several studies measured the same thing in the same unit, we show a simple average and say so. Every result is listed below.
See every resultWhy Saw Palmetto for Prostate Health?
The connection
BPH (enlarged prostate), prostate inflammation, and urinary symptoms.
Also known as: Serenoa repens
Published research
Saw Palmetto × Prostate Health: at a glance
Every published result for this pair, extracted and audited.
These charts count reported findings from published studies, grouped by reported benefit and study design. Study design is not a certainty grade.
Saw Palmetto / Prostate Health: reported findings; one study may contribute several findings.
What the evidence shows
What this means: Counts describe research quantity, not treatment effectiveness or certainty.
| Category | Findings (count) |
|---|---|
| No benefit | 14 |
| Benefit | 3 |
Study designs behind these findings
What this means: Counts describe research quantity, not treatment effectiveness or certainty.
| Category | Findings (count) |
|---|---|
| Meta-analysis | 15 |
| Randomised trial | 2 |
- Studies
- 4
| Study | Outcome | Reported result | Uncertainty (as reported) | Study duration |
|---|---|---|---|---|
| Serenoa repens for the treatment of lower urinary tract symptoms due to benign prostatic enlargement: A systematic review and meta-analysis. (PMID 34488251) | adverse events | Not reported | Not reported | short- and long-term follow-up |
| Serenoa repens for the treatment of lower urinary tract symptoms due to benign prostatic enlargement: A systematic review and meta-analysis. (PMID 34488251) | quality of life | Not reported | Not reported | short- and long-term follow-up |
| Serenoa repens for the treatment of lower urinary tract symptoms due to benign prostatic enlargement: A systematic review and meta-analysis. (PMID 34488251) | urinary symptoms score | Not reported | Not reported | short- and long-term follow-up |
| Comparison of Serenoa repens With Tamsulosin in the Treatment of Benign Prostatic Hyperplasia: A Systematic Review and Meta-Analysis. (PMID 32274957) | Decreased libido | 5.40 | 95% CI [1.17, 24.87]; p = 0.03 | at least 6-month treatment cycle |
| Comparison of Serenoa repens With Tamsulosin in the Treatment of Benign Prostatic Hyperplasia: A Systematic Review and Meta-Analysis. (PMID 32274957) | Ejaculation disorders | 12.56 | 95% CI [3.83, 41.18], p < 0.0001 | at least 6-month treatment cycle |
| Comparison of Serenoa repens With Tamsulosin in the Treatment of Benign Prostatic Hyperplasia: A Systematic Review and Meta-Analysis. (PMID 32274957) | International Prostate Symptom Score (IPSS) | 0.63 | 95% CI [-0.33, 1.59], p = 0.20 | at least 6-month treatment cycle |
| Comparison of Serenoa repens With Tamsulosin in the Treatment of Benign Prostatic Hyperplasia: A Systematic Review and Meta-Analysis. (PMID 32274957) | Maximum flow rate (Qmax) | 0.27 | 95% CI [-0.15, 0.68], p = 0.21 | at least 6-month treatment cycle |
| Comparison of Serenoa repens With Tamsulosin in the Treatment of Benign Prostatic Hyperplasia: A Systematic Review and Meta-Analysis. (PMID 32274957) | Postvoid residual volume (PVR) | -4.23 | 95% CI [-22.97, 14.44], p = 0.65 | at least 6-month treatment cycle |
| Comparison of Serenoa repens With Tamsulosin in the Treatment of Benign Prostatic Hyperplasia: A Systematic Review and Meta-Analysis. (PMID 32274957) | Prostate-specific antigen (PSA) | 0.46 | 95% CI [-0.06, 0.97], p = 0.08 | at least 6-month treatment cycle |
| Comparison of Serenoa repens With Tamsulosin in the Treatment of Benign Prostatic Hyperplasia: A Systematic Review and Meta-Analysis. (PMID 32274957) | Quality of Life (QoL) | 1.51 | 95% CI [-1.51, 4.52], p = 0.33 | at least 6-month treatment cycle |
| Serenoa repens for benign prostatic hyperplasia. (PMID 23235581) | Clinical response | 0.96 risk ratio | 95% CI 0.76 to 1.22 | Not reported |
| Serenoa repens for benign prostatic hyperplasia. (PMID 23235581) | Nightly urination | Not reported | P = 0.19 | Not reported |
| Serenoa repens for benign prostatic hyperplasia. (PMID 23235581) | Peak urine flow | 0.40 mL/s | 95% CI -0.30 to 1.09 | Not reported |
| Serenoa repens for benign prostatic hyperplasia. (PMID 23235581) | Prostate size | -1.22 cc | 95% CI -3.91 to 1.47 | Not reported |
| Serenoa repens for benign prostatic hyperplasia. (PMID 23235581) | Urinary symptoms | 0.25 points | 95% confidence interval (CI) -0.58 to 1.07 | Not reported |
| Saw Palmetto for Symptom Management During Radiation Therapy for Prostate Cancer. (PMID 26891611) | Functional Assessment of Cancer Therapy-Prostate prostate-specific concerns score | Not reported | P = 0.03 | 22 weeks |
| Saw Palmetto for Symptom Management During Radiation Therapy for Prostate Cancer. (PMID 26891611) | International Prostate Symptom Score | Not reported | Not reported | 22 weeks |
Study results, as reported by the publications
Every measured outcome, one row per finding - numbers exactly as reported. Units are preserved where supplied; missing units are not inferred.
| Study and type | Reported sample and duration | Outcome measured | Reported result | What studies found |
|---|---|---|---|---|
| PMID 34488251 2021 Meta-analysis | Sample (as reported): 4,853Duration: short- and long-term follow-up | adverse events | Not reported | No benefit |
| PMID 34488251 2021 Meta-analysis | Sample (as reported): 4,853Duration: short- and long-term follow-up | quality of life | Not reported | No benefit |
| PMID 34488251 2021 Meta-analysis | Sample (as reported): 4,853Duration: short- and long-term follow-up | urinary symptoms score | Not reported | No benefit |
| PMID 32274957 2020 Meta-analysis | Sample (as reported): 1,080Duration: at least 6-month treatment cycle | Decreased libido | 5.40 (95% CI [1.17, 24.87]; p = 0.03) | Benefit |
| PMID 32274957 2020 Meta-analysis | Sample (as reported): 1,080Duration: at least 6-month treatment cycle | Ejaculation disorders | 12.56 (95% CI [3.83, 41.18], p < 0.0001) | Benefit |
| PMID 32274957 2020 Meta-analysis | Sample (as reported): 1,080Duration: at least 6-month treatment cycle | International Prostate Symptom Score (IPSS) | 0.63 (95% CI [-0.33, 1.59], p = 0.20) | No benefit |
| PMID 32274957 2020 Meta-analysis | Sample (as reported): 1,080Duration: at least 6-month treatment cycle | Maximum flow rate (Qmax) | 0.27 (95% CI [-0.15, 0.68], p = 0.21) | No benefit |
| PMID 32274957 2020 Meta-analysis | Sample (as reported): 1,080Duration: at least 6-month treatment cycle | Postvoid residual volume (PVR) | -4.23 (95% CI [-22.97, 14.44], p = 0.65) | No benefit |
| PMID 32274957 2020 Meta-analysis | Sample (as reported): 1,080Duration: at least 6-month treatment cycle | Prostate-specific antigen (PSA) | 0.46 (95% CI [-0.06, 0.97], p = 0.08) | No benefit |
| PMID 32274957 2020 Meta-analysis | Sample (as reported): 1,080Duration: at least 6-month treatment cycle | Quality of Life (QoL) | 1.51 (95% CI [-1.51, 4.52], p = 0.33) | No benefit |
| PMID 23235581 2012 Meta-analysis | Sample (as reported): Not reportedDuration: Not reported | Clinical response | 0.96 risk ratio (95% CI 0.76 to 1.22) | No benefit |
| PMID 23235581 2012 Meta-analysis | Sample (as reported): Not reportedDuration: Not reported | Nightly urination | Not reported (P = 0.19) | No benefit |
| PMID 23235581 2012 Meta-analysis | Sample (as reported): Not reportedDuration: Not reported | Peak urine flow | 0.40 mL/s (95% CI -0.30 to 1.09) | No benefit |
| PMID 23235581 2012 Meta-analysis | Sample (as reported): Not reportedDuration: Not reported | Prostate size | -1.22 cc (95% CI -3.91 to 1.47) | No benefit |
| PMID 23235581 2012 Meta-analysis | Sample (as reported): Not reportedDuration: Not reported | Urinary symptoms | 0.25 points (95% confidence interval (CI) -0.58 to 1.07) | No benefit |
| PMID 26891611 2016 Randomised trial | Sample (as reported): 21Duration: 22 weeks | Functional Assessment of Cancer Therapy-Prostate prostate-specific concerns score | Not reported (P = 0.03) | Benefit |
| PMID 26891611 2016 Randomised trial | Sample (as reported): 21Duration: 22 weeks | International Prostate Symptom Score | Not reported | No benefit |
Published research
Saw Palmetto × Prostate Health: the evidence base
Hand-selected PubMed studies, linked to the originals.
6studies referenced
6journals
2012–2025publication range
Ordered by strength of evidence, then result direction.
01Pathophysiology, conventional treatments, and evidence-based herbal remedies of hair loss with a systematic review of controlled clinical trialsAllam AT, et al. · Naunyn-Schmiedeberg's archives of pharmacology · 2025PMID 40536553 ↗02Effects of dietary supplements on androgenetic alopecia: a systematic review and network meta-analysisZhou L, et al. · Frontiers in nutrition · 2025PMID 41561175 ↗03Serenoa repens for the treatment of lower urinary tract symptoms due to benign prostatic enlargement: A systematic review and meta-analysisTrivisonno LF, et al. · Investigative and clinical urology · 2021PMID 34488251 ↗04Comparison of Serenoa repens With Tamsulosin in the Treatment of Benign Prostatic Hyperplasia: A Systematic Review and Meta-AnalysisCai T, et al. · American journal of men's health · 2020PMID 32274957 ↗05Benign prostate hyperplasia and nutritionDas K, et al. · Clinical nutrition ESPEN · 2019PMID 31451276 ↗06Serenoa repens for benign prostatic hyperplasiaTacklind J, et al. · The Cochrane database of systematic reviews · 2012PMID 23235581 ↗Community experiences
Contributors volunteered; this does not establish treatment effectiveness or population incidence.
Reported changes
No publishable community breakdown is available. This does not establish that no reports exist.
Important: This page reflects observational, aggregate-only community reporting and independent published research. It is not medical advice, and it does not claim any compound treats, cures, or is effective for any condition. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or treatment.